APSI-India’s Post

Infections and immunity grant from the Medical Research Council (MRC) now open. To be eligible for funding to support a research program focusing on infections and immunity, you need to be employed at a research institution that can apply for Medical Research Council (MRC) funding. It is essential to have a track record of successfully securing funding and conducting research. There is no specified limit on the amount of funding you can request, with most applicants seeking £1 million or more. Typically, we cover up to 80% of the total economic cost of your project. The duration of your program can extend up to five years. Participation in the pre-application phase is mandatory, and only selected applicants will proceed to the full application stage. This funding opportunity is available continuously, with application deadlines falling in January, May, and September. https://buff.ly/3TZbFkH At Capti Innovation our mission is to make grant funding more accessible. Every year, we help hundreds of companies save time, win funding and accelerate growth by leveraging our extensive expertise in funding opportunities. Email us for more information [email protected] #funding #investing #fintech #technology #sustainability #growth #cybersecurity #environment #food #automation #automotive #recycling #nutrition #medicine #robotics #farming #augmentedreality #neuroscience #grants #ukgrants #startupgrants #businessgrants #ukgovernmentgrant #sme #smegrant #businessfunding #smefunding #technologygrant #innovationgrant #capti #captiinnovation #gamechanging #gamechanginginnovation #disruptiveinnovation #smartgrant #ai #manufacturing #sustainable #innovation #telecoms #semiconductors #business #IUK #InnovateUK #SmartGrant #InnovateUKfunding

🌍Did you know one of the biggest threats to global health right now is antimicrobial resistance (AMR)? This is when bacteria, viruses, fungi, and parasites no longer respond to the medicines meant to kill them. It affects humans, animals, and our environment! 🌱 🩺The One Health approach is a game-changer in fighting AMR. It connects human, animal, and environmental health to find the best solutions. Here are some key steps we're taking: 🔷Teamwork Across Sectors: Doctors, vets, scientists, and policymakers are working together. 🔷Shared Data: We need to share data across sectors to track AMR and take action. 🔷Education: Teaching everyone—from the public to healthcare professionals—about responsible antimicrobial use. 🔷Better Policies: Creating and enforcing rules for antimicrobial use in farming and healthcare. 🔷Research & Innovation: Finding new medicines, vaccines, and diagnostic tools. 🔷Public Engagement: Getting the public involved in AMR reduction through education and awareness campaigns. Dr. Linda Oyama, a leading scientist in this field highlighted how important it is for everyone to come together and tackle this issue.🐾 👉Read more about integrating One Health principles into antimicrobial stewardship and join the fight against AMR: https://lnkd.in/gy3FxDGR . . . . . . . . . . . . . . #OneHealth #AntimicrobialResistance #AMR #Health #Environment #AnimalHealth #Innovation #PublicHealth #GlobalHealth #Stewardship #Research #Education #Policy MedBound Times NewsGram M Subha M. Sonali Pradhan Jyoti Shukla Susmita Bhandary Munish Kumar Raizada, MD, FAAP Himani Negi Nirainila Joseph Aniket Bakare Dr Pragati Priya Aditi Anup Madathingal Arpit sharma Dr.Amingold M J Rasheeka MP Yogeeta V. Priyanka Pandey Tabsum Baig

𝗨𝗻𝗶𝘁𝗶𝗻𝗴 𝗮𝗴𝗮𝗶𝗻𝘀𝘁 𝗮𝗻𝘁𝗶𝗺𝗶𝗰𝗿𝗼𝗯𝗶𝗮𝗹 𝗿𝗲𝘀𝗶𝘀𝘁𝗮𝗻𝗰𝗲! 💪🏽 In a world where antimicrobial resistance (AMR) poses a huge threat to global health, the need to build capacity in genomics skills and knowledge for surveillance has reached a critical juncture. The time has come for scientists working across human, animal, and environmental health sectors to collaborate, to facilitate the global acceleration of genomics in AMR. Creating spaces for these scientists to exchange knowledge, form new ideas, and learn how to translate data insights into effective decision making is essential for promoting positive public health outcomes. To address this, the Wellcome Connecting Science Learning and Training team and the National Institute for Communicable Diseases (NICD), South Africa, co-organised the first symposium, delivered in conjunction with an AMR training course, to foster discussion on the implementation of genomics into AMR surveillance work across Africa, through the lens of One Health. 𝗥𝗲𝗮𝗱 𝗺𝗼𝗿𝗲 𝗮𝗯𝗼𝘂𝘁 𝘁𝗵𝗶𝘀 𝗽𝗼𝘄𝗲𝗿𝗳𝘂𝗹 𝗰𝗼𝗹𝗹𝗮𝗯𝗼𝗿𝗮𝘁𝗶𝗼𝗻 𝗮𝗻𝗱 𝘁𝗵𝗲 𝗮𝗱𝘃𝗮𝗻𝘁𝗮𝗴𝗲𝘀 𝗳𝗼𝗿 𝗼𝘂𝗿 𝗔𝗠𝗥 𝗰𝗼𝗺𝗺𝘂𝗻𝗶𝘁𝗶𝗲𝘀 𝗶𝗻 𝗔𝗳𝗿𝗶𝗰𝗮 👉🏽 bit.ly/3wZKrSi #AMR #AMRSurveillance #DiseaeSurveillance #Antimicrobialresistance #AMRresearch Wellcome Sanger Institute

𝑬𝒙𝒑𝒂𝒏𝒅𝒊𝒏𝒈 𝑹𝒐𝒍𝒆𝒔 𝒐𝒇 𝑮𝒆𝒏𝒆𝒕𝒊𝒄 𝑪𝒐𝒖𝒏𝒔𝒆𝒍𝒐𝒓𝒔: 𝑻𝒉𝒆 𝑵𝒆𝒆𝒅 𝒇𝒐𝒓 𝑹𝒆𝒈𝒖𝒍𝒂𝒕𝒊𝒐𝒏 𝒊𝒏 𝑪𝒂𝒏𝒂𝒅𝒂 Genetic counselors (GCs) in Canada are increasingly vital across various medical fields, yet they remain largely unregulated. Traditionally confined to genetics clinics, GCs now work autonomously in diverse roles such as labs, research, and public health, significantly impacting patient care. #The Challenge Despite their expanding roles, GCs lack formal legal recognition, leading to inconsistencies in practice and potential ethical issues. Without regulation, there is no standardized certification, posing risks to both practitioners and patients. #The Call for Regulation Regulating GCs would ensure consistent practice standards, enhance the quality of genetic services, and address medical-legal liabilities and title protection. Legal recognition is essential to formalize their roles and safeguard the profession. # Join Us at Health Summit 2024 Explore these crucial issues at Health Summit 2024, hosted by Reboot Communications Ltd. Delve into discussions on genetic counseling, AI in healthcare, and cutting-edge advancements in genomics and longevity. Why Attend: - Stay Informed: Understand the evolving roles and regulatory needs of GCs. - Network: Connect with healthcare professionals and innovators. - Innovate: Discover new approaches in integrating genetics into medical practices. Don't miss this opportunity. Register now at [Health Summit 2024](https://lnkd.in/gX_9zRkX). #GeneticCounseling #HealthcareInnovation #MedicalGenetics #Genomics #AIinHealthcare #PatientCare #HealthcareProfessionals #MedicalEthics #HealthcareRegulation #GeneticServices #HealthcareSummit #HealthSummit2024 #LongevityResearch #GeneticTesting #HealthcareTechnology #HealthPolicy #MedicalResearch #GeneticCounselors #HealthcareLeadership #GeneticAdvancements #HealthEquity #HealthcareTrends #PatientSafety #HealthData #HealthcareNetworking #MedicalAdvancements #HealthConference #Biotech #HealthcareFuture #GeneticMedicine

As public health initiatives evolve, we need to begin to incorporate new initiatives such as genomic testing in order to move forward and make an impact for our aging population. Implementing genomics into public health can help lengthen patient health lifespans by being proactive instead of reactive. Nine out of the 10 leading causes of death and disease in the U.S. can be overridden with our genome. That’s why I’m advocating for pharmacists to be credentialed genomic consultants. It starts with education; We must embrace innovative strategies and integrate them into the medical curriculum. Universities need to take the lead by incorporating these innovative concepts into their curricula and establishing pilot programs to test and refine the new model. #PersonalizedMedicine #Genomics #PharmD #HealthcareInnovation #PatientCare #PracticeOfTheFuture #FutureOfMedicine 

In our ever-evolving world, there are always new ways for health organizations to leverage data and technology to address population health challenges. At Lile Wellness, we believe the key lies with integrating genomic testing at the primary care level for personalized treatments for all patients. More specifically, that key is genomics. Being able to view the genome in its entirety allows preventive care strategies to be identified for individuals at risk for certain diseases, helping inform more targeted and effective public health interventions. It’s vital that we transition from reactive care, to preventive and proactive care.

Hello Everyone, It brings me immense pleasure to share with you all that I have successfully got my first research paper published. This feeling is so overwhelming as it has taken a great deal of effort, inquisitiveness and most importantly, love for understanding the unknown. I am keenly looking forward to witnessing the impact of my work in the scientific space and the opportunities it shall create for further investigations. This is only the first step and it is indeed a positive challenge that I am yet to embrace! The article discusses the virulome and phylogenomic profiling of a novel Burkholderia pseudomallei strain from an Indian clinical isolate, which is responsible for the lethal melioidosis disease. The study contributes to scientific knowledge by enriching the existing knowledge base, identifying virulence factors, and phylogenetic systematics. It also aids in diagnostics, specific anti-microbial therapy, and epidemiological surveillance, enabling physicians to choose effective treatment regimes and save lives. The findings are crucial for health policymakers to control the infective agent and implement appropriate measures in countries with melioidosis. Thanks are due to all co-authors, to my principal investigator, and to the institute for their remarkable contributions and support during the course of this study. This advancement could not have taken place without their assistance and cooperation. Somasish Ghosh Dastidar Chiranjay Mukhopadhyay Ranita Ghosh Dastidar Piyush Behari Lal Rama Rao Damerla Roberto H. Herai Vinod Sundaramoorthy Craig Smith Kasturba Medical College, Manipal Manipal Academy of Higher Education, Center for Emerging and Tropical Diseases, Deakin University #melioidosis #india #infectiousdisease #virulence #antimicrobialresistance #researcharticle #bacteria #diagnosis #healthcare #tropicalinfection #genomics #wgs

What do the Capitol, the White House, and Ovul have in common? The SalivaDirect Conference in Washington, DC! Exciting insights were shared during the Funding Mechanisms and Opportunities Panel on June 5th, featuring Dev Mittar, Paul Eder and Nao Gamo. It was an incredible opportunity to learn about effective pitching and funding pursuits, capped off with a networking happy hour. Key outcomes after the 1st day: - Valuable connections and discussions. - Clarity on #funding mechanisms and pathways. - Promoting collaborations between researchers and businesses in saliva testing. The resounding message? Action is key! We were showcasing #Ovul that is tracking crystallized #saliva patterns to accurately predict ovulation. Our device offers a comfortable, discreet, and non-invasive method for women to manage their fertility. With #AI integration, we enhance the precision and accessibility of this traditional approach. #WomensHealth #Fertility #Innovation #AI #SalivaScience #Ovul #startups #funding #investors #WIB Women In Bio - Engage. Educate. Empower. #NIH National Institute of Allergy and Infectious Diseases (NIAID) #NIAID Biomedical Advanced Research and Development Authority (BARDA) #BARDA #DC #publichealth #health Feel free to reach out if you want to learn more about our technology or share your thoughts on this fascinating intersection of nature and technology!

Our healthcare ecosystem comprises of diverse stakeholders that seeks to develop and deliver innovative health technologies to maximize the benefits to those in need of care while ensuring sustainability. Understanding the true value of health technologies in decision-making is crucial to ensure that treatments are being delivered efficiently while balancing the incentives for continued innovation of technologies that yield a consumer surplus. Value assessment approaches generate signals of the value of health technologies but can also help us understand the prices we see being paid in the market. Sometimes market participants continue to pay more for a medicine than a conventional CEA would suggest is rational, and yet adding a few petals of the value flower can reveal that the market price is actually cost-effective. Especially when coverage decisions are based on CEAs, whether or not a CEA incorporates a value element may have a real impact on people’s lives. It is therefore imperative that we update our approaches to valuing innovative health technologies with GCEA while acknowledging our continued inability to compute the value of all that we actually value. To comprehensively capture the value of health technologies – both cost and benefits – novel and broader sources of value should be incorporated into cost-effectiveness frameworks. GCEA provides a unified, updated inventory of societal value components and recommends best practice guidance to empirically estimate the total value of medical innovation. This paper aims not only to enumerate and define these value components, but also to explain clearly how these can be estimated in practice. By using the GCEA to incorporate comprehensive societal costs and benefits, researchers and policy makers will be able to better appreciate the value that these medical technologies bring to society. ISPOR—The Professional Society for Health Economics and Outcomes Research International Society for Pharmacoepidemiology #valuebasedcare #valueassessment #marketaccess #heor #healtheconomics #healthcare #pharma #patientjourney #patientcentricity #realworldoutcomes #patientoutcomes #costeffectiveness #ispor #hta #healthtechnologyassessment

''When you’re looking at science and laboratory science particularly, people get fixated on the expensive equipment and the fancy technology that surrounds this. But the most important investment in a laboratory is the scientist who is working in the laboratory. All other things aside, their ability to see problems, think of innovative solutions, testing them critically and having an open mind to be able to see through discoveries is a major asset. You invest in your personnel, and you’ve got great science.'' - @John Reeder, Director of TDR Health systems in Low- and Middle-Income Countries (LMICs) are commonly faced with glaring deficiencies in human resources, infrastructure, and funds under the constraints of overwhelming disease burdens. In these already challenging environments, health researchers have had a limited impact on policy and practice. Despite an era of great progress in disease control, most recently with advances in new drugs, vaccines, and vector control technologies, if major disease problems are to be solved, improving the role and performance of collaborative health researchers is tantamount. In this article, Dr. John Reeder, Director of TDR, Wilfried Mutombo Kalonji,Head of Clinical Operations at the Drugs for Neglected Diseases initiative - DNDi and Yasmine Belkaid, President of Institut Pasteur share their insights and experiences on fostering capacity development to transform health research especially in LMICs. Read: https://lnkd.in/dScCmHBB